Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen
Karin Holmsten*, Lise Høj Omland, Anne Birgitte Als, Mads Agerbæk, Line Hammer Dohn, Henriette Lindberg, Niels Viggo Jensen, Andreas Carus, Mette Moe, Abolfazl Hosseini, Cecilia Radkiewicz, Helle Pappot, Anders Ullén
Dive into the research topics of 'Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen'. Together they form a unique fingerprint.